首页 / 院系成果 / 成果详情页

XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer 期刊论文

编号：

6dfd6338-2d41-465b-adf0-04abd7aeefaa
作者：

Zhu, Xiaoli[0]^[1] Sun, Xinchen[1]^[2] Chen, Baoan[2]^[3] Sun, Ning[3]^[4] Cheng, Hongyan[4]^[5] Li, Fan[5]^[6] Zhang, Hongming[6]^[7] Feng, Jifeng[7]^[8] Qin, Shukui[8]^[9] Cheng, Lu[9]^[10] Lu, Zuhong[10]^[11]
地址：

[1]Fudan University Shanghai Cancer Center, Department of Pathology,Shanghai,China
[2]Hospital of Nanjing Medical University, Department of Radiotherapy,Nanjing,China
[3]Southeast University, Department of Hematology and Oncology (Key Department of Jiangsu Medicine),Nanjing,China
[4]Nanjing Forestry University, Department of Automobile and Transportation Engineering,Nanjing,China
[5]Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Department of Breast Surgery,Enshi,China
[6]Taiyuan Li Gong Daxue, State Key Laboratory Breeding Base of Coal Science and Technology Co-founded by Shanxi Province and the Ministry of Science and Technology,Taiyuan,China
[7]Southeast University, Department of Hematology and Oncology,Nanjing,China
[8]Jiangsu Institute of Cancer Institute & Hospital, Department of Medical Oncology,Nanjing,China
[9]s Liberation Army Cancer Center,Nanjing,China
[10]Southeast University, Department of Oncology,Nanjing,China
[11]Southeast University, State Key Laboratory of Bioelectronics,Nanjing,China
语种：

英文
期刊：

Chinese Medical Journal ISSN：0366-6999 2010 年 123 卷 23 期 (3427 - 3432)
收录：
关键词：

Chemotherapy Gene-chip/microarray Non-small-cell lung cancer Single nucleotide polymorphism Xeroderma pigmentosum group C
摘要：

Background Platinum-based chemotherapeutics are the most common regimens for advanced non-small-cell lung cancer (NSCLC) patients, and genetic factors are thought to represent important determinants of drug efficacy. We prospectively assessed the status of the XPC Ala499Val and Lys939Gln gene polymorphisms and investigated whether these SNPs can predict the response to cisplatin/carboplatin-based regimens in advanced NSCLC patients in a Chinese population. Methods The treatment outcomes of 96 advanced NSCLC patients who were treated with platinum-based chemotherapy were evaluated. The polymorphic status of xeroderma pigmentosum group C (XPC) gene was genotyped by the 3-D polyacrylamide gel-based DNA microarray method. Results The distributions of XPC Lys939Gln genotypes differed significantly between the response group (complete + partial responses) and the non-response group (stable + progressive disease; P=0.022). The heterozygous A/C genotype carriers had a poorer response rate than the wild A/A genotype carriers in stage III (OR, 0.074; 95% CI, 0.008-0.704; P=0.023). The XPC Ala499Val polymorphisms were not associated with response to platinum-based chemotherapy. Conclusion Polymorphisms of the XPC gene, Lys939Gln, may be a predictive marker of treatment response for advanced NSCLC patients in stage III.
推荐引用方式
GB/T 7714：

Zhu Xiaoli/55696701800[0],Sun Xinchen/35277753900[1],Chen Baoan/7408611401[2], et al. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer [J].Chinese Medical Journal,2010,123(23):3427-3432.
APA：

Zhu Xiaoli/55696701800[0],Sun Xinchen/35277753900[1],Chen Baoan/7408611401[2],Sun Ning/35367161400[3],&Lu Zuhong/55637289700[10].(2010).XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer .Chinese Medical Journal,123(23):3427-3432.
MLA：

Zhu Xiaoli/55696701800[0], et al. "XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer" .Chinese Medical Journal 123,23(2010):3427-3432.

浏览次数：4  下载次数：0

分享到：

浏览次数：4

下载次数：0

打印次数：0